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Most cases of Parkinson’s disease (PD) are sporadic. When choosing an animal model for idiopathic PD, one must consider the
extent of similarity or divergence between the physiology, anatomy, behavior, and regulation of gene expression between humans
and the animal. Rodents and nonhuman primates are used most frequently in PD research because when a Parkinsonian state is
induced, they mimic many aspects of idiopathic PD. These models have been useful in our understanding of the etiology of the
disease and provide a means for testing new treatments. However, the current animal models often fall short in replicating the true
pathophysiology occurring in idiopathic PD, and thus results from animal models often do not translate to the clinic. In this paper
we will explain the limitations of animal models of PD and why their use is inappropriate for the study of some aspects of PD.
1.Introduction
The goal of most studies focused on understanding idio-
pathic PD is to identify the triggers and the mechanisms
involved in the progressive neurodegeneration associated
with the disease, to design treatments for the symptoms
and to develop strategies to slow or stop neurodegeneration.
Ideally, a model of idiopathic PD would be progressive in
nature allowing the characterization of mechanistic changes
in the brain and the onset of symptoms with time. Such
a model would provide an opportunity to intervene as
the disease progressed. Toxin-based models fall short in
this regard since their acute nature, a single or a few
injections given over a short period of time followed by rapid
or immediate onset of symptoms, limits their usefulness.
In addition, the best animal models should mimic the
pathophysiology of the disease including the formation
of alpha, synuclein, containing inclusions (Lewy bodies),
the loss of neurons in the substantia nigra pars compacta
(SNpc), and behavioral symptoms that arise during the
course of the disease [1]. Taking these important issues
into consideration, the best animal models for PD would
provide a gradual onset of pathophysiological symptoms
and only after manifestation of symptoms would a drug
or neuroprotective agent be administered to test for eﬀec-
tiveness [2]. When a genetic model is used to study PD,
treatment could be administered prior to the onset of
the symptoms. This clinically driven approach that mimics
the development of the disease in patients is rarely used
in animal studies although there are a few exceptions
[3, 4].
A widerange of models have been used to study PD
from the small evolutionarily remote single cell yeast to
the large evolutionarily similar nonhuman primate. Yeast
[5], worms [6], and fruit ﬂies [7] are useful for studying
fundamental cellular processes involved with PD, such as
apoptosis, autophagy, oxidative stress, protein misfolding
and degradation, vesicle-mediated transport, and determin-
ing the function of proteins. Some of the factors known to
be involved with PD have no known homologs in the smaller
eukaryotes, nevertheless expression of human genes in these
organisms has been useful in partially elucidating the role
of the proteins. Whether it is possible to entirely determine
the function of proteins using heterologous expression
remains unclear particularly because important protein-
protein interactions may not be evolutionarily conserved. In
addition, these small animal models cannot be used to study
manyoftheclinicalmanifestationsofthedisease[8],norcan
yeast, worms, or fruit ﬂies replicate the loss of neurons in the
brain [7].
Throughout the years of PD research, rodents have been
widely used to study the disease because they are readily2 Parkinson’s Disease
available, genetically malleable, and relatively low cost as
compared to larger animals. There are several excellent
studies that have used dogs, cats and nonhuman primates for
PD studies, but the ethical concerns and costs of such studies
have limited their utility. Because of the widespread use of
rodent models and their similarities to humans, they will be
the focus of this paper.
2. ModelingPD inRodents Using
EnvironmentalToxins
To the best of our knowledge, PD does not appear to develop
naturally in any animals except humans. The standard
models for PD are designed to produce nigrostriatal
dopaminergic lesions usually with 6-hydroxydopamine
(6-OHDA), 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP),paraquator,rotenone[9–12].Mostofthesemodels
inhibit mitochondrial function and/or create reactive oxygen
species, but none of them completely reproduces the clinical
symptoms and pathology of PD seen in humans [12].
Although these models are used extensively to study the
mechanism of disease onset and progression and the eﬃcacy
of therapeutic treatments, the results obtained using these
models rarely translate to the clinic successfully [13, 14]. Part
of the problem with most of the toxin models is their acute
nature, which is completely diﬀerent from the insidious
progression of PD observed in patients. Compensatory
changes may arise in patients over the course of the disease
that would not have an opportunity to occur in the acute
animal models. In addition, PD occurs most frequently
in elderly patients, usually around the age of 60 or older.
Unfortunately, most rodent models do not use older animals
because of the inconvenience and cost of housing the
animals for an extended period of time. In addition, a closer
look at the diﬀerences in behavior, physiology, and gene
expression between rodents and humans as described below
partially reveals why the animal studies do not translate well
to clinical studies.
3.CanGeneticModelsBeUsed to
Study Idiopathic PD?
Some recently developed models for studying idiopathic PD
have taken advantage of either genes known to play a role
in PD from familial studies or genes whose expression is
signiﬁcantly altered in PD patients compared to controls.
Models using inherited mutated familial genes are designed
to create null mutations of recessive genes or to express
additional copies of dominant genes in mice. The genetic
models have recently been reviewed elsewhere and therefore
are not described in detail in this paper except for a few of
the most promising recently developed models [15, 16]. One
of the mouse models expresses the human α-synuclein gene
with two mutations (A30P/A53T) that produce dominantly
inherited forms of PD under the control of the tyrosine
hydroxylase (TH) promoter that restricts expression to
catecholaminergic neurons [17]. The beneﬁt of this genetic
model is that an age-dependent loss of TH-positive neurons
intheSNpcisobservedalongwithadeclineinmotoractivity.
No Lewy bodies are observed in this model however. In
addition, there are no known familial cases of PD in which
both mutations have arisen in the α-synuclein gene, thus
the relevance of the model has been questioned [15]. In
another approach to developing genetic models, transgenic
mice were created that used the TH promoter to overexpress
truncated forms of α-synuclein [18, 19] that had been shown
to be pathologically relevant to PD [20–23]. One of these
models showed selective nigral DA neuron degeneration and
impaired locomotive function that was reversed by L-DOPA
treatment similar to PD in humans [19]. Unfortunately,
the loss of neurons in this model was not progressive and
occurred during embryogenesis thus substantially reducing
the value of this model for collecting information pertinent
toPDinhumans.Analternativeapproachforoverexpressing
α-synuclein is stereotactic injection of the gene carried on
viral vectors into the SN which produced rodents with DA
neuron degeneration [24–26]. Despite the availability of
numerous α-synuclein- based genetic models of PD, only the
mouse prion promoter A53T α-synuclein transgenic mouse
shows the same α-synuclein pathology and age-dependent
neurodegeneration that is observed in humans [27–30]. One
of the most recent additions to the selection of α-synuclein
models of PD is a transgenic mouse that expresses the wild
type gene with the regulated tetracycline (tet) system [31].
In this model, loss of neurons in the SN, progressive motor
decline, hippocampal pathology and cognitive impairment
were observed, but there were no ﬁbrillary inclusions.
This model has provided one very important piece of
information in understanding PD, however. The ability to
terminate expression allowed the investigators to conclude
that continual expression of α-synuclein was required for
disease progression [31].
There has been much more limited success in producing
a genetic model of PD using several autosomal recessive
genes including Parkin, PINK1 and DJ-1 (reviewed in [15]).
Recently more attention has been directed at LRRK2 since
mutations in this gene account for 5%–6% of patients with
familial PD and 1%–3% of sporadic PD patients [32, 33].
Unfortunately, most of the transgenic mice that express wild
type or mutated versions of LRRK2 exhibit minimal or no
neurodegeneration [16]. This is also true of the wild type
and mutant LRRK2 bacterial artiﬁcial chromosome (BAC)
transgenic mice [34]. Despite this caveat, an advantage of the
LRRK2BACtransgenicmiceisthattheyexhibitaprogressive
age-dependent motor deﬁcit that responds to L-Dopa and
apomorpine treatment [35].
Promising alternatives to the strict genetic models are
genetic models that are additionally exposed to toxins such
as MPTP. Since the development of PD may be caused by
exposure to environmental toxins or heavy metals combined
withageneticvulnerability,thesenewercombinationmodels
could prove to be extremely beneﬁcial for studying PD. In
addition,someofthemorereﬁnedgeneticmodelsofPDalter
the expression of genes of interest in speciﬁc regions of the
brain or speciﬁcally in neurons. One of the most promising
models in this category is the MitoPark mouse [36]. In this
model the mitochondrial transcription factor TFAM mayParkinson’s Disease 3
be conditionally inhibited in dopamine neurons. MitoPark
mice exhibit motor impairment, reduced dopamine in the
striatum and loss of dopamine neurons particularly in the
SNpc. Intracellular aggregates form in the brain of MitoPark
mice, but unfortunately they are not similar to the Lewy
bodies that form in PD patients.
4. BehavioralTests
Part of the problem with studying PD in animals is not
simply the model, that is chosen, but in addition the assays
usedtoassesschangesbetweenthehealthyanddiseasedstate.
PD patients experience many motor symptoms including
akinesia, bradykinesia, muscular rigidity, dystonia, resting
tremors, gait abnormalities and postural instability due
to progressive dopamine neuron loss and dysregulation of
dopamine-modulated pathways in the basal ganglia [37, 38].
When assessing behavioral changes in rodent models, it is
important to keep in mind that although the neuroanatom-
ical components underlying motor control may be similar
for humans and rodents, the manifestation of these motor
deﬁcits may be expressed diﬀerently between species.
There are various behavioral tests for rodents that are
used to measure dopamine-induced motor deﬁcits in animal
models of PD. For example, there are exploratory tests such
as the open ﬁeld test and swim test, and then there are
learned and/or innate skill tests. The latter tests include the
rotarod, grid test, adjusting steps, inclined beam traversal,
climbing down a pole, forelimb placing test, reaction-time
test, staircase test, paw retraction test, adhesive removal
and nesting behavior (for a full description of the tests see
[37, 39]). These behavioral tests were largely designed to
assess the innate motor skills/abilities of animals that are
dopamine dependent,in ordertorelatethechangesobserved
to the motor deﬁcits seen in PD patients. However, many
of these behavioral tests (with the exception of the stepping
test) require the animal to learn the task ﬁrst as most of these
measures are complex tasks. Complex tasks can still measure
innate motor skills though one does not know if the failure
to perform a task is from a motor deﬁcit or from a learning
deﬁcit. It is important to note that not all animals learn these
complex tasks even prior to receiving the dopamine lesion
and often are excluded from the results. In the animals that
do learn the behavioral tasks one must keep in mind that
the tests are reﬂective of akinesia and bradykinesia, and not
necessarily tremor and rigidity. Although there are behav-
ioral models that measure tremor and rigidity [39] the latter
two symptoms are subtler and would probably be easier to
characterize if rodents were less dependent on all four limbs
forbalance(formoreinformationseeTimothySchallert’slab
website: http://homepage.psy.utexas.edu/homepage/group/
SchallertLAB/). To date, there are no behavioral models that
can reproduce all of the motor deﬁcits that are commonly
seen to be in PD patients.
Another key point to consider is that the design of the
paradigm inﬂuences the behavioral outcome. For example,
the degree of dopamine loss, the timing and dose of the toxin
injections, the time between injections and the behavioral
testing and genetic manipulations will all impact the results
of the behavioral study. When comparing the MPTP and 6-
OHDA lesion models, the MPTP model would seem more
favorable as it produces a bilateral dopamine lesion that
can be delivered using a chronic regime [40, 41], similar
to the slow onset of idiopathic PD, whereas the 6-OHDA
model is classically a unilateral lesion [42], although bilateral
lesionshavebeenestablished[43–45].Intheclassicunilateral
6-OHDA model only a single injection into the medial
forebrain bundle is required to induce a full dopamine lesion
approximately 2 weeks after injection. This is similar to what
is seen in the bilateral 6-OHDA lesion models. The bilateral
lesion models may be considered more relevant to PD since
both hemispheres are dopamine depleted and they can have
more speciﬁcity towards behavioral impairments depending
on the dose and location of the injections [46]. Although
both 6-OHDA models reproduce the major behavioral
deﬁcits seen in PD, the eﬀect of the 6-OHDA toxin does not
mimic the progressive loss seen in PD. The MPTP model
also has its own caveats in that the extent of neuropathology
observed is dependent on the age, sex, and strain of mouse
used in the study [47]. In addition, the MPTP mouse models
(as with the other toxin models of PD) fail to encompass the
wide assortment of motor impairments seen in PD patients
[37, 48]. Perhaps the current rodent models of PD would be
more predictive of what will translate into human studies if
the time course of dopamine neuron degeneration could be
mimicked and behavioral tests were designed to assess the
more subtle symptoms of tremor and rigidity.
Beyond the paradigm chosen for a particular study,
there is a concern that applies to all animal research that is
often neglected when interpreting results. There are factors
introduced to the everyday laboratory environment by the
experimenter that can cause undue stress to the animals.
For example, rodents by nature are social creatures, and
follow a social dominance hierarchy. Often a dominant
male will suppress his subordinate cage mates by ﬁght-
ing and/or guarding the food and water to establish the
hierarchy. Social interactions of this nature can lead to
changes in dietary intake and overall behavior, an unwanted
situation when conducting a behavioral experiment. The
animals can also identify with the experimenter’s smell (e.g.,
perfumes/colognes and scents from shampoos, deodorant,
laundry soaps and lotions), including that of their lab coat.
By using one speciﬁc lab coat only for behavioral testing
throughout the entire experiment, animals can identify with
the experimenter’s smell and may be less stressed by their
presence. Overall, it is important that investigators consider
these subtle, though potentially important, confounds to
their work.
5.Physiological Concerns
Although there is a great deal of similarity between the phys-
iology of rodents and humans, it is clear that signiﬁcant dif-
ferences exist. Perhaps one of the most relevant examples of
this diﬀerence with regards to PD research is the distinction
between how humans and rodents metabolize MPTP. Rats4 Parkinson’s Disease
and mice are relatively resistant to MPTP, whereas humans
are quite sensitive to this toxin. The sensitivity of humans to
MPTP became apparent in 1983 when several drug addicts
unfortunately injected themselves with MPTP thinking it
was synthetic heroin. These young drug addicts very quickly
developed symptoms similar to PD [49]. In contrast to this,
MPTPismoreeﬀectivewhenadministeredwiththeadjuvant
probenecid (which blocks the rapid clearance of MPTP
and its metabolites from the kidney) in rodents in order
to produce some of the pathophysiological and behavioral
symptoms seen in humans [40, 41]. There are likely to be
additional diﬀerences in the metabolism of environmental
toxins between rodents and humans that have not yet been
identiﬁed and, therefore investigators must remain cautious
in interpreting the results from studies of rodent models.
Diﬀerences between the blood brain barrier in humans
and rodents must also be considered in this regard. There
is evidence that the neuroinﬂammation associated with PD
may make the blood brain barrier more leaky than in a
healthy individual [50]. The function of the blood brain
barrier is to act as a physical and metabolic barrier between
the blood and central nervous system. If this barrier becomes
leaky, immune mediators of the blood may enter the brain
and contribute to the neurodegenerative process. Similar to
humans,thebloodbrainbarrieralsobecomesleakyinrodent
models of PD [50]. The brain endothelial cells from rodents
do not express the same enzymes as humans, however, and
therefore the inﬂux of nutrients that nourish the brain and
eﬄux of toxic metabolites may be diﬀerent between the
species [50]. The transporter diﬀerences in the blood brain
barrier between species again suggest that caution is required
when applying data from animal studies to humans.
6. Regulation of Gene Expression
In the past, it was thought that transcription factors were
conserved in sequence and function, allowing regulation of
the same target genes across species. Recent studies, however,
have now shown that although transcription factors may
be conserved across species, the sites which they bind are
diﬀerent [51]. The divergence in the cis-regulatory networks
between humans and mice was demonstrated in hepatocytes
[52]. When the transcription factor binding sites in human
chromosome 21 are compared to the orthologous regions
in mice, only one-third to a half are conserved [53]. When
mouse transcription factors were placed in a mouse nuclear
environment, a human-like binding signature was observed
onahuman-derivedchromosomeindicating thatthehuman
chromosomal sequence is responsible for the placement of
the transcription factors [53]. Studies similar to this have
not yet been done in the brain, but the existence of cis-
regulatory species-speciﬁc networks suggest that we cannot
assume that the regulation of gene expression will be the
same between humans and the animal models used for PD
research. In this regard, major diﬀerences in the expression
of transcription factors were observed between human and
chimpanzees brains, which most likely results in coordinated
diﬀerences in the expression of downstream genes [54].
Of particular interest to PD research, diﬀerences between
the transcription regulation of human and mouse tyrosine
hydroxylase have already been noted [55]. This is of interest
because tyrosine hydroxylase is the enzyme that catalyzes
the hydroxylation of tyrosine to produce L-dopa [56], which
is the rate-limiting step in the synthesis of catecholamine
neurotransmitters [57].
Species diﬀerences in posttranscriptional regulation of
gene expression are just as important to consider as tran-
scriptional changes when evaluating animal models. The
regulation of alternative splicing plays an essential role in
the diversity of proteins produced from a single gene. To
determine the extent of alternative splicing in diﬀerent
species, Brett and colleagues studied expressed sequence
tags and determined that the extent of alternative splicing
is similar among species including humans and rodents
[58]. Recently, however, it was shown that humans have
more regulated alternative splicing than rodents using a
similar approach [59]. The diﬀerent results obtained in
these two studies are most likely due to the fact that the
newer study used only bona ﬁde alternative splicing events,
along with a few additional diﬀerences in the methodology
[59]. Although some alternative splicing events have been
evolutionarily conserved, the majority of these events have
not been conserved between humans and mice [60]. With
regard to the most prevalent form of alternative splicing,
exon skipping, it has been estimated that >11% of the events
are species-speciﬁc [61]. The results from all these studies
combined suggest that species-speciﬁc alternative splicing
has the potential to produce large diﬀerences in phenotypic
complexity. These ﬁndings suggest that we must use caution
when interpreting results from studies of animal models of
PD because subtle molecular changes at the level of gene
expression may result in large changes in signaling pathways
and behavioral and physiological responses.
In addition to splicing changes in gene expression, non-
coding microRNAs (miRNAs) ﬁne-tune gene expression by
binding to RNA sequences within the 3 -untranslated region
and usually downregulate gene expression by destabilizing
the RNA or inhibiting translation. Many miRNAs have
been evolutionarily conserved, and there are many highly
conserved motifs in the 3  untranslated region of mRNAs in
vertebrates, some of which most likely bind miRNAs [62].
Unfortunately, very few of the putative miRNA binding sites
thathavebeenidentiﬁedthroughbioinformaticsstudieshave
been experimentally tested. Because of the importance of
using animal models for studying diseases, further studies
designed to assess the degree of evolutionary conservation of
miRNA regulation of gene expression between species would
be extremely helpful.
7. Conclusions
Rodents and nonhuman primates are an important resource
for the study of PD, but the limitations of these models
must be kept in mind when interpreting results. Nonhu-
man primate models are anatomically, physiologically, and
behaviorally more similar to humans, but they are rarelyParkinson’s Disease 5
used because of cost and ethical concerns. Rats and mice
are widely used for modeling PD, but no toxin or genetic
model completely reproduces the pathophysiology seen in
humans. Because it is currently thought that environmental
factors and genetic susceptibility play a role in the onset and
progression of PD, perhaps the most promising models are
those that combine genetic models with exposure to toxins.
Because of the current limitations with PD models, some
studies are best done in the clinic. An example of this type
of study would be the search for noninvasive biomarkers
of PD. If one is attempting to identify blood biomarkers
of PD, the investigation could be done directly in humans
and therefore the results obtained from the study would be
directly applicable to patients.
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